Cathie Wood Sheds $5M In CRISPR Therapeutics, Scoops Up These Biotech Stocks Instead

Cathie Wood-led Ark Investment Management on Thursday sold 70,723 shares of gene editing company CRISPR Therapeutics AG CRSP, valued at over $5.58 million, via its flagship fund.

For ARK Innovation ETF ARKK, CRISPR is its fifth largest holding with a weight of 4.83%, according to holdings data on the firm's website as of Thursday.

The flagship fund currently holds over 6 million shares in CRISPR valued at over $493 million. During the end of July, its CEO Samarth Kulkarni sold 25,000 shares, SEC filings showed.

Also Read: Alibaba Slips 1%, Nio, XPeng Rise Over 3%: Hang Seng Opens Firmer After Mixed Wall Street Session

Analyst Rating: Citigroup has increased the price target on the firm’s shares to $83, while maintaining a "neutral" rating, according to data from Benzinga Pro.

Stock Movement: The stock ended Thursday up 0.42% at $78.91.

Other Trades: ARKK bought 28,048 shares of cancer diagnostics firm EXACT Sciences Corporation EXAS, valued at over $1.38 million based on the stock's last close. EXACT Sciences is the sixth largest holding of the fund at a weight of 4.66%. The stock closed 3.72% higher on Thursday.

The fund also bought 113,483 shares of Pacific Biosciences of California Inc PACB shares, valued at over $650,000 as of Thursday’s close.

The fund currently holds over 13.8 million shares in the firm valued at over $72 million, with a weight of 0.71%. Pacific Biosciences shares ended 11.52% higher at $5.81 on Thursday.

Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsBroad U.S. Equity ETFsShort IdeasSpecialty ETFsSmall CapMarketsTrading IdeasETFsGeneralARK Investment ManagementCathie WoodEurasia
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!